Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Depreciation & Amortization (CF) (2016 - 2025)

Seres Therapeutics' Depreciation & Amortization (CF) history spans 11 years, with the latest figure at $1.0 million for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 25.64% year-over-year to $1.0 million; the TTM value through Sep 2025 reached $4.3 million, down 29.11%, while the annual FY2024 figure was $5.5 million, 12.41% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $1.0 million at Seres Therapeutics, down from $1.1 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.7 million in Q3 2022 and bottomed at $1.0 million in Q3 2025.
  • The 5-year median for Depreciation & Amortization (CF) is $1.5 million (2021), against an average of $1.4 million.
  • The largest annual shift saw Depreciation & Amortization (CF) grew 18.16% in 2022 before it tumbled 33.52% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.6 million in 2021, then rose by 4.83% to $1.6 million in 2022, then rose by 0.31% to $1.6 million in 2023, then tumbled by 33.52% to $1.1 million in 2024, then dropped by 3.78% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Depreciation & Amortization (CF) are $1.0 million (Q3 2025), $1.1 million (Q2 2025), and $1.1 million (Q1 2025).